Insights

Prescription for Trouble: Why Employers Must Act Now on Pharmacy Fiduciary Oversight

Learn More

2025 FDA Q1 Drug Approvals and Launches to Watch: Stelara Biosimilars, Non-Opioid Pain Relief & More

Learn More

GLP-1s, Weight Loss & Rising Drug Spend: How Employers Can Adapt

Learn More

The Power of Independent PBM Rebate Reconciliation 

Learn More

Pricing Guarantee Reconciliation

Navion conducted an independent rebate and discount reconciliation for a 3,400-life group, uncovering $660,000 in rebates and discounts value initially missed by the PBM’s
Learn More

Navigating the Changing Landscape of Pharmacy Rebates: What Self-Funded Employers Need to Know

Learn More

The Biosimilar Shift: How New Options for Stelara and Humira are Reshaping Specialty Care for Payers

The biosimilar landscape is continuing to rapidly evolve, and 2025 marks a pivotal year for payers seeking cost-saving opportunities. With Stelara biosimilars making their
Learn More

Filter Insights:

Join our newsletter to stay up to date on market trends.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

Latest Clinical Insight

Prescription for Trouble: Why Employers Must Act Now on Pharmacy Fiduciary Oversight

AlignRx is Now Navion